SOPHARMA AD - Sales revenues for December 2025

Spis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Spis załączników:

1. SFA_Sales_Revenues_December_2025_EN_espi.pdfSales revenues for December 2025
   

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No 20 / 2026

Date of issue: 2026-01-20

Short name of the issuer

SOPHARMA AD

Subject

Sales revenues for December 2025

Official market - legal basis

Art. 56. 1. 2 of Act on Public Offering

Unofficial market - legal basis

Contents of the report:

Sofia, Bulgaria, January 20, 2026 – According to the requirements of Art. 100t of the Law on Public Offering of Securities (LPOS), “Sopharma” AD (SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) notifies, that for December 2025 the Company recorded increase in sales of 39% compared to the same month of the previous year, incl. 50% increase in domestic sales and 31% increase in export sales.
For 2025, the Company has achieved sales increase of 14%, including 5% increase in domestic sales and 20% increase in export sales.

Annexes

File Description

SFA_Sales_Revenues_December_2025_EN_espi.pdfSFA_Sales_Revenues_December_2025_EN_espi.pdf Sales revenues for December 2025

SOPHARMA AD

(fullname of the issuer)

SOPHARMA AD Farmaceutyczny (far)

(short name of the issuer) (sector according to clasification of the WSE in Warsow)

1220 Sofia

(post code) (city)

IlienskoShosse 16

(street) (number)

[phone] [phone]

(phone number) (fax)

(e-mail) (web site)

nd

(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Date Name Position / Function Signature

2026-01-20 Ognian Ivanov Donev Executive Director